A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-07-28
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-25 (study day 14); relationship: N
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-10 (study day 30); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-10-19 (study day 69); relationship: not assessed
moderate
assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-01-10 (study day 152); relationship: not assessed
Data queries
No data queries.